OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 - ...

Cash and cash equivalents were approximately $110.8 million as of December 31, 2024. “I am extremely pleased with the progress we made last ...

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; ...

a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine ...

As a crucial cellular process involved in degrading and recycling damaged organelles and proteins, autophagy-related (ATG) proteins mediated autophagy plays a significant role in various physiological ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. BridgeBio Oncology Therapeutics, a cancer drug ...

Patient dosing in a Phase 1 trial for that drug could start later this year. A third prospect mutes signaling between two proteins, PI3Ka and RAS, that are implicated in tumor growth. It’s in an early ...

65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on ...